Speaker Profile
Ph.D., VP, Orphan Diseases, Tempus AI
Biography
Danielle brings a decade-plus of leadership in rare disease therapeutics, having managed cross-functional teams in both biotechnology startups and major pharmaceutical firms. She is highly regarded for her expertise in the strategic development of AI-enabled diagnostic tools, accelerating the identification and treatment of rare conditions. Her portfolio includes overseeing clinical research, business development, and patient engagement, with a strongcommitment to improving health outcomes among underserved populations. Danielle holds advanced degrees in both science and business administration.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair: Catriona Jamieson, UCSD
PMWC Award Ceremony Honorees
• Judy Faulkner, Epic
• Svetlana Mojsov, The Rockefeller University (GLP-1)
• Alexis C. Komor, UCSD
Opening Talk
• Catriona Jamieson, UC San Diego
GLP-1: From Hormone Discovery to a Global Therapeutic Revolution
• Svetlana Mojsov, The Rockefeller University
What’s Next at Epic?
• Peter DeVault, Epic
Modified mRNA, siRNA, ASOs
• Chair: Alexis C. Komor, UC San Diego
• Niren Murthy, UC Berkeley
• Gene Yeo, UC San Diego
• Reuben Harris, UT Health San Antonio
Stem Cell–Targeted Therapeutics: Small Molecules & Biologics
• Chair: Catriona Jamieson, UC San Diego
• Irving L. Weissman, Stanford
In Vivo Gene Therapies
• Chair: Gene Yeo, UC San Diego
• Mark A. Kay, Stanford
• David Schaffer, UC Berkeley
Diagnostics, Prognostics, and Patient Stratification
• Chair: Ezra Cohen, Tempus
• Eitan Ruppin, NIH
• Danielle Hamel, Tempus
• David Ledbetter, Florida State University
• Ludmil Alexandrov, UC San Diego
Closing
• Catriona Jamieson, UC San Diego
